FLT3 and acute myeloid leukemia: We conducted a multicenter, retrospective study including 171 adult patients with R/R FLT3‐mutated AML who received gilteritinib as third‐line or beyond between August 2017 and March 2024 across centers in Italy, Spain, the United Kingdom, and Turkey.